Advertisement

Misconceptions and Facts About ‘Diastolic’ Heart Failure

  • Edgar Argulian
    Correspondence
    Requests for reprints should be addressed to Edgar Argulian, MD, MPH, Division of Cardiology, Mt Sinai St Luke's and Roosevelt Hospitals, Mt Sinai Health System, 1111 Amsterdam Ave, New York, NY 10025.
    Affiliations
    Division of Cardiology, Mt Sinai St Luke's and Roosevelt Hospitals, Mt Sinai Health System, New York, NY
    Search for articles by this author
  • Franz H. Messerli
    Affiliations
    Division of Cardiology, Mt Sinai St Luke's and Roosevelt Hospitals, Mt Sinai Health System, New York, NY
    Search for articles by this author

      Abstract

      Heart failure with preserved ejection fraction has become a fashionable diagnosis. An increasing number of elderly patients with dyspnea carry this diagnosis. Evaluation and management of these patients typically labeled as having “diastolic” heart failure are challenging, and misconceptions are common. No drug class has been shown to consistently provide outcome benefit. Therapeutic strategies based on the predominant pathophysiologic mechanism and stage of the disease currently remain the best option in tackling the perplexing syndrome of heart failure with preserved ejection fraction.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nagueh S.F.
        • Appleton C.P.
        • Gillebert T.C.
        • et al.
        Recommendations for the evaluation of left ventricular diastolic function by echocardiography.
        J Am Soc Echocardiogr. 2009; 22: 107-133
        • Komajda M.
        • Lam C.S.
        Heart failure with preserved ejection fraction: a clinical dilemma.
        Eur Heart J. 2014; 35: 1022-1032
        • Redfield M.M.
        • Jacobsen S.J.
        • Burnett Jr., J.C.
        • et al.
        Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.
        JAMA. 2003; 289: 194-202
        • Abhayaratna W.P.
        • Marwick T.H.
        • Smith W.T.
        • Becker N.G.
        Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey.
        Heart. 2006; 92: 1259-1264
        • Persson H.
        • Lonn E.
        • Edner M.
        • et al.
        Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES.
        J Am Coll Cardiol. 2007; 49: 687-694
        • Kraigher-Krainer E.
        • Shah A.M.
        • Gupta D.K.
        • et al.
        Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
        J Am Coll Cardiol. 2014; 63: 447-456
        • Borlaug B.A.
        • Redfield M.M.
        • Melenovsky V.
        • et al.
        Longitudinal changes in left ventricular stiffness: a community-based study.
        Circ Heart Fail. 2013; 6: 944-952
        • Argulian E.
        • Agarwal V.
        • Makani H.
        • et al.
        Association of exercise tolerance with effective arterial elastance obtained noninvasively in patients with exertional dyspnea.
        J Am Soc Echocardiogr. 2014; 27: 675-679
        • Wan S.H.
        • Vogel M.W.
        • Chen H.H.
        Pre-clinical diastolic dysfunction.
        J Am Coll Cardiol. 2014; 63: 407-416
        • Vogel M.W.
        • Slusser J.P.
        • Hodge D.O.
        • Chen H.H.
        The natural history of preclinical diastolic dysfunction: a population-based study.
        Circ Heart Fail. 2012; 5: 144-151
        • Lam C.S.
        • Lyass A.
        • Kraigher-Krainer E.
        • et al.
        Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community.
        Circulation. 2011; 124: 24-30
        • Zile M.R.
        • Gaasch W.H.
        • Anand I.S.
        • et al.
        Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.
        Circulation. 2010; 121: 1393-1405
        • Hachamovitch R.
        • Hayes S.W.
        • Friedman J.D.
        • et al.
        A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy.
        J Am Coll Cardiol. 2005; 45: 722-729
        • Argulian E.
        • Agarwal V.
        • Bangalore S.
        • et al.
        Meta-analysis of prognostic implications of dyspnea versus chest pain in patients referred for stress testing.
        Am J Cardiol. 2014; 113: 559-564
        • Argulian E.
        • Halpern D.G.
        • Agarwal V.
        • et al.
        Predictors of ischemia in patients referred for evaluation of exertional dyspnea: a stress echocardiography study.
        J Am Soc Echocardiogr. 2013; 26: 72-76
        • Bhatia R.S.
        • Tu J.V.
        • Lee D.S.
        • et al.
        Outcome of heart failure with preserved ejection fraction in a population-based study.
        N Engl J Med. 2006; 355: 260-269
        • Halley C.M.
        • Houghtaling P.L.
        • Khalil M.K.
        • et al.
        Mortality rate in patients with diastolic dysfunction and normal systolic function.
        Arch Intern Med. 2011; 171: 1082-1087
        • Abidov A.
        • Rozanski A.
        • Hachamovitch R.
        • et al.
        Prognostic significance of dyspnea in patients referred for cardiac stress testing.
        N Engl J Med. 2005; 353: 1889-1898
        • Yamamoto K.
        • Origasa H.
        • Hori M.
        Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF).
        Eur J Heart Fail. 2013; 15: 110-118
        • Massie B.M.
        • Carson P.E.
        • McMurray J.J.
        • et al.
        Irbesartan in patients with heart failure and preserved ejection fraction.
        N Engl J Med. 2008; 359: 2456-2467
        • Yusuf S.
        • Pfeffer M.A.
        • Swedberg K.
        • et al.
        Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
        Lancet. 2003; 362: 777-781
        • Pitt B.
        • Pfeffer M.A.
        • Assmann S.F.
        • et al.
        Spironolactone for heart failure with preserved ejection fraction.
        N Engl J Med. 2014; 370: 1383-1392
        • Redfield M.M.
        • Chen H.H.
        • Borlaug B.A.
        • et al.
        Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
        JAMA. 2013; 309: 1268-1277
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
        Circulation. 2013; 128: 1810-1852
        • Shah S.J.
        Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter.
        J Am Coll Cardiol. 2013; 62: 1339-1342
        • McMurray J.J.
        • O'Connor C.
        Lessons from the TOPCAT trial.
        N Engl J Med. 2014; 370: 1453-1454
        • Kosmala W.
        • Holland D.J.
        • Rojek A.
        • et al.
        Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
        J Am Coll Cardiol. 2013; 62: 1330-1338